COVID-19 pneumonia.
Conditions
Interventions
Intervention group: Patients in this group will receive drug regimen including Tab hydroxychloroquine 400 mg twice daily on day 1 then 200 mg twice daily + Tab lopinavir/ritonavir 200/50 mg two tablet
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with highly suspected or confirmed COVID-19 who are candid for hospitalization and starting triple-drug combination
Exclusion criteria
Exclusion criteria: History of drug allergy Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical response. Timepoint: Every other day. Method of measurement: Evaluation of clinical signs and symptoms.;Paraclinical response. Timepoint: Every other day. Method of measurement: Laboratory and radiological findings.;Adverse drug reactions. Timepoint: Every other day. Method of measurement: Interview and laboratory data. | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of hospitalization. Timepoint: End of hospitalization. Method of measurement: Medical records.;Clinical outcome. Timepoint: End of study. Method of measurement: Patient's record. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein Khalili
Tehran University of Medical Sciences
Outcome results
None listed